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Background: Hypertension is a very common cardiovascular disease influenced by multiple genetic and
environmental factors. More recently, there are some studies showed that mutations in mitochondrial DNA have
been involved in its pathogenesis. In this study we did further investigations on this relationship.
Methods: Epidemiological research found a Han Chinese family with probable maternally transmitted hypertension.
Sequence analysis of the whole mitochondrial DNA was detected from all the family members. And evaluations of
the clinical, genetic and molecular characterization were also performed.
Results: Matrilineal relatives within the family exhibited varying degrees of hypertension with an onset age of
48–55 years. Sequence analysis of this pedigree showed a novel homoplasmic 4329C > G mutation located at the
3’ end of the tRNAIle and tRNAGln genes that was absent from 366 Chinese controls. The cytosine (C) at 4329
position was very important in the structural formation and stabilization of functional tRNAs, which was highly
conserved in mitochondria of various organisms and also contributed to the high fidelity of the acceptor arm. Cells
carrying this mutation were also shown to harbor mitochondrial dysfunctions.
Conclusions: The C4329G point mutation in tRNAIle and tRNAGln was involved in the pathogenesis of hypertension,
perhaps in association with other modifying factors.
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Essential hypertension (EH) is one of the most important
modifiable risk factors for cardiovascular disease (CVD)
and renal disease in worldwide. In China, there is a preva-
lence estimate of 27.9%, or 133 million, hypertensive adults
[1]. Hypertension is also a major risk factor for the develop-
ment of CVD and renal morbid- and fatal events [2].
The etiology of hypertension is not well understood
because it can be caused by single or multiple genetics, and
also associated with environmental and other individual* Correspondence: gminxin88@gmail.com; ametuofo980869@163.com
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reproduction in any medium, provided the orfactors. Of the genetic factors, maternal transmission of
hypertension has been implicated in some pedigrees, sug-
gesting that mutations in mitochondrial DNA (mtDNA)
may contribute to the pathogenesis of EH [3-7]. More re-
cently, several mtDNA point mutations have been proved
in association with hypertension. These mutations include
T3308C in ND1 [8], A4435G in tRNAMet [9], A4295G
and A4263G in tRNAIle [10,11], and A4401G in tRNAMet
and tRNAGln [12].
To identify novel mtDNA mutations involved in the
pathogenesis of hypertension in Chinese population,
we initiated a systematic and extended mutational screening
of mtDNA in a large cohort of hypertension subjects from
the Geriatric Cardiology Clinic at the Chinese PLA General
Hospital. Here, we reported a novel point mutation C4329G
in tRNAIle and tRNAGln genes carried by a Chinese Han
family with maternally inherited hypertension.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Figure 1 Pedigree chart of the Chinese family with hypertension. Affected individuals are indicated by filled symbols. Arrowhead denotes proband.
Liu et al. BMC Medical Genetics 2014, 15:84 Page 2 of 7
http://www.biomedcentral.com/1471-2350/15/84Methods
Subjects
As part of a genetic screening program for hypertension,
a Chinese Han family with maternal inherited hypertension
was found at the Institute of Geriatric Cardiology at the
Chinese PLA General Hospital. An experienced physician
measured the systolic and diastolic blood pressures of sub-
jects with a mercury column sphygmomanometer using aTable 1 Summary of clinical data of the members in the Chin






II-1 M 63 - 132
II-2* F 60 50 160
II-3 M 61 - 128
II-4 F 58 - 120
II-5 M 68 - 124
II-6 F 62 - 130
II-7 M 70 - 132
II-8* F 64 55 150
II-9 M 56 - 128
II-10 F 52 - 120
II-11 M 53 - 124
II-12 F 50 - 132
II-13* M 54 48 140
II-14 F 50 - 128
III-1 M 40 - 130
III-2 M 38 - 128
III-3 F 35 - 118
III-4 M 33 - 120
III-5 M 40 40 150
III-6 M 39 - 124
III-7 F 44 43 160
III-8 M 30 - 116
III-9 F 28 - 128
III-10 M 28 - 126
III-11 M 25 - 130
III-12 F 27 - 120
*These patients received antihypertension treatment. This table shows pretreatmen
male; IVST, interventricular septal thickness; LVH, ECG showed left ventricular hyperstandard protocol. The first and the fifth Korotkoff sounds
were taken to be indicative of systolic and diastolic blood
pressures, respectively. The average of three such readings
was taken as the examination blood pressure. Hypertension
was defined according to the recommendation of the
Joint National Committee on Detection, Evaluation and
Treatment of High Blood Pressure (JNC VI) [13] as a







60 10 N 89.1
80 12 LVH 81.2
68 11 N 102.8
60 10 N 103.5
58 9 N 87.9
60 10 N 86.5
70 10 N 92.6
80 12 LVH 72.3
64 9 N 82.3
66 11 N 87.4
60 10 N 92.7
68 11 N 86.9
100 11 N 83.2
60 9 N 119.2
60 8 N 122.3
58 8 N 130.2
60 9 N 118.6
58 9 N 108.6
90 12 N 89.1
60 9 N 121.3
90 13 LVH 71.2
60 8 N 114.5
70 9 N 134.8
70 9 N 107.9
70 10 N 126.7
58 9 N 139.6
t blood pressures. CCr indicates endogenous creatinine clearance; F, female; M,
trophy; N, electrocardiography (ECG) was normal.
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the members of this family underwent a thorough phys-
ical examination, a laboratory assessment of CVD risk
factors, and routine electrocardiography (Figure 1). All
subjects were evaluated to identify both personal and
medical histories of hypertension and other clinical ab-
normalities. DNA samples of the family and 366 healthy
controls were aquired for sequence analysis. Informed
consents were obtained from all participating members,
under protocols approved by the ethics committee of
the Chinese PLA General Hospital.
mtDNA sequencing and analysis
Genomic DNA was isolated from whole blood cells of
participants using Puregene DNA Isolation Kits (Gentra
Systems, Minneapolis, MN). The entire mitochondrialFigure 2 Identification and qualification of the 4329C > G mutation
tRNAGln genes. (A) Schema of the location of 4329C > G in the precurs
mitochondrial tRNAIle and tRNAGln are derived from Florentz et al. [4]. Pr
were determined for RNase Z. Arrow indicates the position of the 4329C
tRNAGln genes from an affected individual (II-2) and a married-in control
position 4329.genome of all the participants were PCR-amplified in 24
overlapping fragments using sets of light-strand and
heavy-strand oligonucleotide primers [14]. Each frag-
ment was purified and subsequently analyzed by direct
sequencing in an ABI 3700 automated DNA sequencer
(Applied Biosystems, Inc., Foster City, CA) using the Big
Dye Terminator Cycle sequencing reaction kit. The resultant
sequence data were compared with the revised consensus
Cambridge sequence (GenBank accession no. NC-012920)
[15]. All mtDNA mutations were individually analyzed using
the MitoAnalyzer (National Institutes of Standards and
Technology, Gaithersburg, MD; http://www.cstl.nist.gov/
biotech/strbase/mitoanalyzer.html) and the MITOMAP
database [16]. The haplogroups were deduced by compar-
ing the complete mtDNA sequence data with previously
reported haplogroup-specific variants [17].at the junction between mitochondrial tRNAIle and
ors of tRNAIle and tRNAGln genes. Cloverleaf structures of human
ocessing sites in the mitochondrial tRNAIle and tRNAGln precursors
> G mutation. (B) Partial sequence chromatograms of tRNAIle and
(II-1). Arrow indicates the location of the base changes at
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Clinical presentation
The proband (II-2) presented with essential hypertension
with onset age of 50 years old. Her medical history reported
a highest blood pressure reading of 220/120 mm Hg. She
first underwent full evaluation at the Chinese PLA General
Hospital Geriatric Cardiology Clinic at the age of 60 with a
blood pressure 160/80 mm Hg. She suffered from head-
aches when her blood pressure exceeded 200/100 mmHg,
and took oral reserpine and aspirin to prevent stroke
when it ranged between 140/80 and 160/100 mmHg.
She was diagnosed with diabetes mellitus two years ago
for which she was administered oral metformin. La-
boratory tests showed a normal range of liver function,
normal cholesterol levels, and mild kidney dysfunction
(creatinine clearance rate, 81.2 ml/min). Kidney dysfunc-
tion was secondary to hypertension. The ECG showed left
ventricular hypertrophy. Physical examination revealed
no other clinical abnormalities, including hyperlipidemia,
vision and hearing impairments, and neurological disor-
ders associated with mitochondrial DNA muation.
The proband’s family located in Shanxi Province in
Northern China (shown in Figure 1), the family presented
with a maternal inheritance of hypertension. Her mother
(I-2) was diagnosed with hypertension at 60 years of age,
with a blood pressure of 180/100 mm Hg. She has three
brothers and three sisters; one brother (II-13) and one sister
(II-8) presented with high blood pressure at the age ofFigure 3 Alignment of tRNAIle genes from different species. Arrow ind
corresponding to the C > G at position 4329.48 years and 55 years, respectively. One of her nieces (III-7)
and one of her nephew (III-5) also had hypertension with
an onset age of 43 and 40 years old. None of the offspring
of the affected father had hypertension. The clinical data of
other family members were showed in Table 1.
Mitochondrial DNA analysis
Since the transmission pattern of this family presented
with maternal inherited hypertension, we supposed that
mtDNA maybe involved in the pathogenesis. So we did
further analyze on the mitochondrial genome of the family
members. We did analyze on the entire mitochondrial
gene using PCR amplification and subsequent sequence
analysis of PCR fragments derived from proband II-2 and
an unrelated Chinese control. As shown in Figure 2B, the
point mutation C4329G in tRNAIle and tRNAGln genes was
identified in the proband. Sequencing of the PCR fragment
spanning the tRNAIle and tRNAGln genes revealed that this
mutation was absent from 366 Chinese controls.
And all the family members had did sequence analysis.
All the 14 maternal lineage except the pedigree (I-2), car-
ried the C4329G mutation in tRNAIle and tRNAGln genes.
The other non-maternal members had no this point muta-
tion. And in these 14 maternal members, there are 5 of
them had presented with hypertension. More important,
her nieces (III-7) and nephew (III-5) also had hypertension
with an onset age of 43 and 40 years old, respectively. And
it is very important that none of the offspring of the affectedicates the position of the Acc-stem 71 at the anticodon loop of tRNA,
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analysis on the pedigree, and except for autosomal reces-
sive, autosomal dominant, X-linked patterns. By far the
mitochondrial point mutation is the most likely explanation
of etiology of hypertension for this pedigree.
The C4329G mutation, as shown in Figure 2A, is located
at the 3’ end of the acceptor arm of tRNAIle and tRNAGln
[4,18]. Figure 3 presented us that the cytosine residue at
this position is highly conserved in all known tRNAIle
and tRNAGln sequences [4,18]. In fact, nucleoside
modifications at this position play a pivotal role in theTable 2 mtDNA variants in 1 Han Chinese subject (II-2) with h
Gene Position Replacement Conservation (H/M/B/X)* rC
D-loop 73 A to G
152 T to C
263 A to G
310 T to C
489 T to C
12SrRNA 1382 A to C A/G/G/C
1438 A to G A/A/C/A
16SrRNA 2706 A to G A/G/G/A
3010 G to A G/T/G/A
ND1 3975 C to T C/C/A/C
4260 C to T C/M/C/T
tRNA Ile 4329 C to G C/C/C/C
tRNA Met 4467 C to A C/C/C/C
COII 8020 G to A G/P/C/A
ATPase8 8414 C to T C/A/C/A
ATPase6 8701 A to G A/I/F/T
COIII 9824 T to A T/F/L/C
ND3 10398 A to G A/E/E/A
10400 C to T C/I/T/E
ND4 10873 T to C T/T/T/C
11984 T to A T/A/S/T
ND6 14580 A to T
14587 A to C
14605 A to G
14668 C to T
Cytb 14783 T to C T/F/K/A
15043 G to A
15301 G to A
15326 A to G A/L/S/A
D-loop 16223 C to T
16311 T to C
16362 T to C
*Data show the conservation of amino acid for polypeptides or nucleotide for rRNA
†Cambridge sequence.
‡See http://www.mitomap.org.stabilization of the tertiary structure and the tRNAs’
function [19]. The C4467A mutation in tRNAMet gene
which was evolutionary conserved, but was not de-
tected in other maternal members.
To further identify the phenotypic manifestation, DNA
fragments spanning the entire mtDNA of the proband
II-2 were PCR-amplified. Each fragment was purified and
subsequently analyzed by direct sequencing. As shown in
Table 2, a comparison of the resultant sequences with the
Cambridge consensus sequence and control subject iden-
tified a number of nucleoside changes belonging to theypertension and 1 Han Chinese control subject
RS† II-2 Control Previously reported‡ Amino acid change
A G G Y
T C C Y
A G G Y
T C C Y
T C C Y
A C C Y rRNA
A G G Y rRNA
A G G Y rRNA
G A A Y rRNA
C T C Y syn
C T T Y syn
C G C N
C A C N
G A A Y syn
C T T Y L-F
A G G Y T-A
T A A Y syn
A G G Y T-A
C T T Y syn
T C C Y syn
T A T Y Y-H
A T T Y syn
A C C Y syn
A G G Y syn
C T T Y syn
T C C Y syn
G A A Y syn
G A A Y syn
A G G Y T-A
C T T Y
T C C Y
T C C Y
s, in human (H), mouse (M), bovine (B), and Xenopus laevis (X).
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polymorphisms in the D-loop region, three variants in the
12S rRNA gene, one in the 16S rRNA gene, two in the
ND1 gene, a C4329G mutation in the tRNAIle and
tRNAGln genes, one variant in the COII gene, one in the
COIII gene, one in each of the ATPase6 and ATPase8
genes, two in the each of the ND3 and ND4 genes, and
four in each of the ND6 and Cytb genes [21]. Those tRNA,
rRNA, and polypeptide variants were further evaluated by
phylogenetic analysis of sequences from other organisms
such as mouse [22], cow [23] and Xenopus laevis [24].
However, none of the polypeptide variants were highly
conserved evolutionarily, indicating that they do not have
a significant functional consequence.
Discussion
EH is currently regarded as a multifactorial CVD, which
may be influenced by both genetic and/or environmental
factors. The role of genetic factors in the etiology of
hypertension is improved by cross-sectional studies of
familial aggregation of the disorder despite exposure to
different environmental factors [10,25]. Estimates of
genetic variance range from 20–50% [26], and signifi-
cant blood pressure correlations between mothers and
offspring or excess maternal transmission of hyperten-
sion have been noted in several earlier [8,25] and more
recent [8-12] investigations.
In this study, we performed the clinical, genetic mo-
lecular investigation of a Chinese family with hyperten-
sion. Hypertension as a sole clinical phenotype was
only presented in all matrilineal relatives of this three-
generation pedigree, suggesting that the mtDNA muta-
tion (s) is involved in this disorder. Mutational analysis of
the mitochondrial genome identified the novel mutation
4329C > G in tRNAIle and tRNAGln in matrilineal relatives
of this Chinese family. The absence of this mutation from
366 Chinese controls strongly suggests that it is involved
in the pathogenesis of hypertension. There are 32 variants
identified belonging to the Eastern Asian haplogroup H2
on the maternal lineage. Thirty variants were the known
polymorphisms, 4329C > G and 4467C > A were novel var-
iants, but 4467C > A were not identified in other maternal
members (not detected in II-8, II-13). The 4329C > G is
located in the acceptor arm of tRNAIle and tRNAGln,
which is a 7-base pair stem made by the base pairing of
the 5′-terminal nucleotide with the 3′-terminal nucleo-
tide. This contains the CCA 3′-terminal group that is used
to attach the amino acid. Pre-tRNA 3’ ends are subse-
quently completed by the addition of the CCA triplet, and
a subset of nucleotides becomes post-transcriptionally
modified. Finally, mature and correctly folded tRNAs
are esterified at the 3’ end with the cognate amino acid
by the corresponding aminoacyl-tRNA synthetase. These
are subsequently transported to the ribosome by thetranslation factor elongation factor (EF)-Tu, enabling
protein synthesis to occur. In addition, 4329 was located
at the cleavage sites of tRNAase Z, so this substitution
could impair (or not) the cleavage and processing of the
policistronic mtRNA transcripts into mature mt-tRNA
species. Thus, 3’ end metabolism is important for both
tRNA synthesis and function, as shown by a previous re-
port by Guan et al. in which a Chinese family with Leber’s
hereditary optic neuropathy was found to be associated
with the homoplasmic A15951G mutation located adja-
cent to the 3’ end [27].
Conclusions
In summary, the occurrence of the 4329C > G mutation
in the Chinese Han family pedigree with hypertension
and its absence in 366 Chinese controls and the observed
mitochondrial dysfunctions in cells carrying the mutation
suggest that it is involved in the pathogenesis of hyperten-
sion. However, as hypertension is a complex CVD associ-
ated with multiple genetic and environmental factors,
disease pathogenesis may result from this point mutation
in association with other modifier factors.
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